Theracryf Plc(LSE) TCF

Market Cap£4.78M

Since IPO (2015)-99%

5 Year-97%

1 Year-17%

1 Month+0%

£0.00

+5.88%

+0.00Today

Theracryf Plc last closing stock price
Metric	Price	Date
Last close	GBX 0.18	2026-10-23

Theracryf Plc stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	GBX 0.18	2026-10-16
1 month	+0%	GBX 0.18	2026-09-23
3 month	-16.67%	GBX 0.21	2026-07-24
Year to date	-12.5%	GBX 0.20	2025-12-31
1 year	-16.67%	GBX 0.21	2025-10-23
3 year	-91.03%	GBX 1.95	2023-10-24
5 year	-97.01%	GBX 5.85	2021-10-22
Since inception	-99.49%	GBX 0.35	2015-10-21

Theracryf Plc Financials at a Glance

Market Cap

£4.78M

Revenue (TTM)

£0.00

Net Income (TTM)

-£5.47M

EPS (TTM)

-£0.00

P/E Ratio

-1.09

Dividend

£0.00

Beta (Volatility)

-0.10 (Low)

Dividend

£0.00

Beta (Volatility)

-0.10 (Low)

Price

£0.00

Volume

2,812,681

Open

£0.00

Price

£0.00

Volume

2,812,681

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.00

Estimated Earnings Date

Dec 17, 2026

Dividend

£0.00

Beta (Volatility)

-0.10 (Low)

Price

£0.00

Volume

2,812,681

Open

£0.00

Previous Close

£0.00

Daily Range

£0.00 - £0.00

52-Week Range

£0.00 - £0.00

Estimated Earnings Date

Dec 17, 2026

TCF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theracryf Plc

Evgen Pharma plc is a UK-based pharmaceutical company focused on developing innovative sulforaphane-based medications to combat various cancers and inflammatory conditions. Founded in 2014, the company utilizes its proprietary Sulforadex technology to stabilize sulforaphane, with its lead drug candidate, SFX-01, currently in clinical trials.

Products and Services

SFX-01: Lead drug candidate for metastatic breast cancer and glioblastoma
Preclinical investigations for haematological malignancies
Out-licensing services for proprietary technology

Growth Outlook

Ongoing Phase II trials for SFX-01 indicate potential market entry
Strong focus on expanding research into additional cancer types
Partnership opportunities may enhance development capabilities

Financial Highlights

Recent quarterly revenue of 396,000 GBP shows growth from previous periods
Cash reserves of 2,004,000 GBP as of March 2024 support ongoing operations
Operating expenses reflect significant investment in research and development

Evgen Pharma plc is positioned in the biotechnology sector, with a clear focus on addressing unmet medical needs through innovative therapies. The company's lead candidate, SFX-01, is undergoing critical clinical trials, which could pave the way for future revenue streams. The financial data indicates a commitment to research and development, essential for long-term growth. With a solid cash position, Evgen Pharma is well-equipped to navigate the challenges of clinical development and capitalize on potential market opportunities.

AI Generated • Oct 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Huw Jones, PhD

Website

www.evgen.com

Headquarters

Nether Alderley, CH SK10 4TG, GB

TCF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-93.92%

Return on Capital

-135.08%

Return on Assets

-73.35%

Earnings Yield

-91.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£4.78M

Shares Outstanding

2.73B

Volume

2.81M

Avg. Volume

3.03M

Financials (TTM)

Gross Profit

-£913.00K

Operating Income

-£5.82M

EBITDA

-£5.67M

Operating Cash Flow

-£4.92M

Capital Expenditure

-£17.00K

Free Cash Flow

-£4.94M

Cash & ST Invst.

£1.54M

Total Debt

£11.00K

Theracryf Plc Performance Analysis

Theracryf Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-03-31	GBP 442,000	N/A
2024	2024-03-31	GBP 396,000	-10.4%
2025	2025-03-31	GBP 0	N/A
2026	2026-03-31	GBP 0	N/A

Theracryf Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-09-30	N/A
Q4	2025-03-31	N/A
Q2	2025-09-30	N/A
Q4	2026-03-31	N/A

Theracryf Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-03-31	GBP -0.01	48.5%
2024	2024-03-31	GBP -0.01	-22.4%
2025	2025-03-31	GBP -0.00	-68.4%
2026	2026-03-31	GBP -0.00	-55.6%

Theracryf Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-09-30	26.2%
Q4	2025-03-31	75.6%
Q2	2025-09-30	100.0%
Q4	2026-03-31	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£12.00K

-140.0%

Gross Margin

0.00%

N/A

Market Cap

£4.78M

N/A

Market Cap/Employee

£531.28K

N/A

Employees

N/A

Net Income

-£2.22M

-32.2%

EBITDA

-£2.31M

-10.0%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

£1.54M

-23.0%

Total Debt

£11.00K

N/A

Accounts Receivable

£747.00K

+50.3%

Inventory

£0.00

+100.0%

Long Term Debt

£0.00

N/A

Short Term Debt

£11.00K

N/A

Return on Assets

-73.35%

N/A

Return on Invested Capital

-1.18%

N/A

Free Cash Flow

-£1.87M

-8.2%

Operating Cash Flow

-£1.85M

-7.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PRM.LProteome Sciences plc

PRM.LProteome Sciences plc£0.01-0.37%

TRX.LTissue Regenix Group plc

TRX.LTissue Regenix Group plc£0.07+0.00%

N4P.LN4 Pharma Plc

N4P.LN4 Pharma Plc£0.00+0.00%

CRTX.LCRISM Therapeutics Corporation

CRTX.LCRISM Therapeutics Corporation£0.09+0.00%

FDBK.LFeedback plc

FDBK.LFeedback plc£0.07+0.00%

OBD.LOxford BioDynamics Plc

OBD.LOxford BioDynamics Plc£0.00+4.55%

VAL.LValiRx plc

VAL.LValiRx plc£0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$147.49+1.89%

TAT&T

TAT&T$20.93-7.96%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$83.56+1.77%

NUNu Holdings

NUNu Holdings$15.16+2.92%

NOKNokia

NOKNokia$8.14+3.30%

EWZiShares - iShares Msci Brazil ETF

EWZiShares - iShares Msci Brazil ETF$42.59+1.77%

NVDANvidia

NVDANvidia$210.96-0.59%

Questions About TCF

What is the current price of Theracryf Plc?

Theracryf Plc is trading at £0.00 per share.

What is the 52-week range for Theracryf Plc?

Over the past 52 weeks, Theracryf Plc has traded between £0.00 and £0.00.

How much debt does Theracryf Plc have?

As of the most recent reporting period, Theracryf Plc reported total debt of £11.00K.

How much cash does Theracryf Plc have on hand?

Theracryf Plc reported £471.00K in cash and cash equivalents in its most recent financial results.

What is Theracryf Plc’s dividend yield?

Theracryf Plc does not currently have a dividend yield.

Theracryf Plc(LSE) TCF

Theracryf Plc Financials at a Glance

TCF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Theracryf Plc

TCF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Theracryf Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About TCF

What is the current price of Theracryf Plc?

What is the 52-week range for Theracryf Plc?

How much debt does Theracryf Plc have?

How much cash does Theracryf Plc have on hand?

What is Theracryf Plc’s dividend yield?

Premium Investing Services